CINECA IRIS Institutional Research Information System

Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement

Fagioli, Franca;
2015-01-01
2015
HAEMATOLOGICA
100
3
99
101
http://www.haematologica.org/content/haematol/100/3/e99.full.pdf
AIEOPt(8;21); AML; AML1-ETORUNX1-RUNX1T1; CBFB-MYH11; Inv(16); Molecular MRD; Pediatric; RQ-PCR; Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Monitoring; Etoposide; Female; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mutation; Neoplasm, Residual; Proto-Oncogene Proteins; RUNX1 Translocation Partner 1 Protein; Survival Analysis; Transcription Factors; Translocation, Genetic; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Hematology
Pigazzi, Martina*; Manara, Elena; Buldini, Barbara; Beqiri, Valzerda; Bisio, Valeria; Tregnago, Claudia; Rondelli, Roberto; Masetti, Riccardo; Caterin...espandi
03A-Articolo su Rivista
File in questo prodotto:
File Dimensione Formato  
e99.full.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 171.44 kB
Formato Adobe PDF
Visualizza/Apri
171.44 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1690508
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 34
social impact